Publications & Presentations
Developing ‘once-and-done’ gene editing medicines to treat cardiovascular disease
EAS
VERVE-101,
VERVE-201,
GalNAc-LNP
2023
ANGPTL3,
PCSK9
TIDES 2023 Keynote Address
TIDES
VERVE-101,
VERVE-201
2023
ANGPTL3,
PCSK9
Innovative LNPs for Gene Editing Applications
TIDES
GalNAc-LNP
2023
ANGPTL3,
PCSK9
Preclinical Data Supporting Potential Efficacy of VERVE-201, an Investigational Base Editing Medicine Targeting ANGPTL3
ACC
VERVE-201,
GalNAc-LNP
2023
ANGPTL3
An in vivo CRISPR base editing therapy to inactivate ANGPTL3: nomination of a development candidate for VERVE-201 [presentation]
ESC
VERVE-201,
GalNAc-LNP
2022
ANGPTL3
An in vivo CRISPR base editing therapy to inactivate ANGPTL3: nomination of a development candidate for VERVE-201 [poster]
ESC
VERVE-201,
GalNAc-LNP
2022
ANGPTL3
Disrupting the care of cardiovascular disease with single-course gene editing medicines
ASGCT
VERVE-101,
VERVE-201,
GalNAc-LNP
2022
ANGPTL3,
PCSK9